Carroll Financial Associates’s BioMarin Pharmaceuticals BMRN Stock Holding History

Carroll Financial Associates’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$26K	Hold	294	–	–	﹤0.01%	896
2021 Q3	$22K	Hold	294	–	–	﹤0.01%	966
2021 Q2	$24K	Hold	294	–	–	﹤0.01%	1025
2021 Q1	$22K	Buy	+294	New	+$24K	﹤0.01%	984
2016 Q2	–	Sell	-18	Closed	-$1K	–	1135
2016 Q1	$1K	Buy	+18	New	+$1.47K	﹤0.01%	1071
2014 Q4	–	Sell	-45	Closed	-$3K	–	743
2014 Q3	$3K	Hold	45	–	–	﹤0.01%	702
2014 Q2	$3K	Hold	45	–	–	﹤0.01%	770
2014 Q1	$3K	Buy	+45	New	+$3.32K	﹤0.01%	709

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Carroll Financial Associates's BMRN Position: Q4 2021 in Review

Carroll Financial Associates held its BioMarin Pharmaceuticals (BMRN) position steady in Q4 2021 at 294 shares worth $26K. The position accounts for ﹤0.01% of the portfolio, ranked #896.

Carroll Financial Associates first reported a position in BMRN in Q1 2014 and has held it in 8 quarters since. 557 funds tracked by Wall St. Rank hold BMRN as of Q4 2021.

Carroll Financial Associates held 294 shares of BioMarin Pharmaceuticals worth $26K as of Q4 2021.
Carroll Financial Associates left its BioMarin Pharmaceuticals share count unchanged in Q4 2021.
BioMarin Pharmaceuticals made up ﹤0.01% of Carroll Financial Associates's portfolio in Q4 2021, its #896 holding.
Carroll Financial Associates first reported a position in BioMarin Pharmaceuticals in Q1 2014 and has held it in 8 quarters since.
557 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2021.

Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.